<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03156933</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL16_0800</org_study_id>
    <nct_id>NCT03156933</nct_id>
  </id_info>
  <brief_title>Alternative Splicing and Leukemia Initiating Cells</brief_title>
  <acronym>ASLIC</acronym>
  <official_title>Alternative Splicing and Leukemia Initiating Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aberrant RNA splicing and mutations in spliceosome complex in acute myeloid leukaemia (AML)
      are frequent. It have been shown that some splicing variants had a prognostic value in AML.

      AML are characterized by their propensity to relapse because of the persistence of leukaemia
      initiating cells (LICs).

      The aim of this study is to determine the splice variants on AML initiator cells and define a
      splicing pattern.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2017</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Polymerase chain reaction</measure>
    <time_frame>1 month</time_frame>
    <description>Transcriptome analysis to determine the splicing variants on acute myeloid leukaemia initiator cells.
The analysis will focus on the gene encoding ABCA3 transporter and genes known to be mutated in patients with acute myeloid leukemia (FLT3, NPM1, c-Kit, N et K-RAS).
The duration of selection of samples is estimated to be one month.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ribonucleic acid sequencing</measure>
    <time_frame>1 month</time_frame>
    <description>Transcriptome analysis to determine the splicing variants on acute myeloid leukaemia initiator cells.
The analysis will focus on the gene encoding ABCA3 transporter and genes known to be mutated in patients with acute myeloid leukemia (FLT3, NPM1, c-Kit, N et K-RAS).
The duration of selection of samples is estimated to be one month.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Splicing variants</arm_group_label>
    <description>Sample of acute myeloid leukaemia primary cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Assessment of splicing variants</intervention_name>
    <description>This is a biological study with primary samples without any intervention on patients.</description>
    <arm_group_label>Splicing variants</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      RNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with 11q23 acute myeloid leukaemia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years-old

          -  Patients treated at the south lyon hospital center

          -  Patients with a diagnosis of acute myeloid leukemia confirmed in cytology and whose
             involvement of the 11q23 locus was confirmed by in situ hybridization

          -  Patients for whom a sample is available in the cytogenetic laboratory of the south
             lyon hospital center

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Etienne PAUBELLE, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service d'hématologie du Centre Hospitalier Lyon Sud</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Etienne PAUBELLE, MD, PhD</last_name>
    <phone>04 78 86 22 50</phone>
    <phone_ext>+33</phone_ext>
    <email>Etienne.paubelle@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eric WATTEL, MD, PhD</last_name>
    <phone>04 78 86 22 60</phone>
    <phone_ext>+33</phone_ext>
    <email>eric.wattel@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service d'hématologie du Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Etienne PAUBELLE, MD, PhD</last_name>
      <phone>04 78 86 22 50</phone>
      <phone_ext>+33</phone_ext>
      <email>Etienne.paubelle@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Erice WATTEL, MD, PhD</last_name>
      <phone>04 78 86 22 60</phone>
      <phone_ext>+33</phone_ext>
      <email>eric.wattel@chu-lyon.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2017</study_first_submitted>
  <study_first_submitted_qc>May 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2017</study_first_posted>
  <last_update_submitted>May 16, 2017</last_update_submitted>
  <last_update_submitted_qc>May 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

